SCHEMBL7919601

SCHEMBL7919601

c1ccc(NC2CCC2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPT P10636 1/20 0.53
NOS2 P35228 1/20 0.52
KDM4E B2RXH2 4/20 0.52
GAA P10253 2/20 0.52
GRM5 P41594 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HCAR3 P49019 2/20 0.49
GPR39 O43194 2/20 0.48
NPC1 O15118 1/20 0.47
PKM P14618 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.45
MAPK10 P53779 1/20 0.45
GFER P55789 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 2/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16548498 0.96 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL1579641 0.94 KDM4E (0.60) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL29211498 0.92 KDM4E (0.58) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL526424 0.92 NOS2 (0.55) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
Hydrochloric Acid SCHEMBL1919379 0.90 NOS2 (0.54) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL25091032 0.83 NOS2 (0.52) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL20024991 0.83 NOS2 (0.52) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E
SCHEMBL17730325 0.83 MERTK (0.55) ALDH1A1SMN1; SMN2MAPTNOS2GAA
SCHEMBL3235320 0.83 MAPK1 (0.62) ALDH1A1SMN1; SMN2MAPTNOS2GRM5
SCHEMBL31690862 0.83 NOS2 (0.52) ALDH1A1SMN1; SMN2MAPTNOS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2025-06-05 US disclosed
EP-3031799-B1 AROMATIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-04-04 EP disclosed
US-9776962-B2 Aromatic compounds with GPR40 agonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
EP-3031799-A1 AROMATIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-15 EP disclosed
US-20160115128-A1 AROMATIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-04-28 US disclosed
CN-102574845-A 1h-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG 2012-07-11 CN disclosed
US-6211220-B1 ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS CELL PATHWAYS, INC. 2001-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115128-A1 AROMATIC COMPOUND GLP1R, GPR119, GPR39 ALDH1A1 3137/4885SMN1; SMN2 1516/4885MAPT 3476/4885
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF RIPK1, RIPK2, RIPK3 ALDH1A1 4611/4885SMN1; SMN2 1610/4885MAPT 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.